{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:03:34Z","timestamp":1790741014815,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T00:00:00Z","timestamp":1785024000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002551","name":"Seoul National University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002551","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.tranon.2026.102958","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T20:09:50Z","timestamp":1785355790000},"page":"102958","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["In vitro evaluation of sacituzumab govitecan in non-small cell lung cancer with actionable genomic alterations"],"prefix":"10.1016","volume":"72","author":[{"given":"Yerim","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soyeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6145-4426","authenticated-orcid":false,"given":"Tae Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4064-4199","authenticated-orcid":false,"given":"Miso","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeonghwan","family":"Youk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5124-7132","authenticated-orcid":false,"given":"Dong-Wan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8196-4247","authenticated-orcid":false,"given":"Bhumsuk","family":"Keam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.tranon.2026.102958_bib0001","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.tranon.2026.102958_bib0002","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1038\/s41416-025-03139-6","article-title":"Refining treatment strategies for non-small cell lung cancer lacking actionable mutations: insights from multi-omics studies","volume":"133","author":"Rocca","year":"2025","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.tranon.2026.102958_bib0003","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41392-025-02243-6","article-title":"Advances in molecular pathology and therapy of non-small cell lung cancer","volume":"10","author":"Huang","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"3","key":"10.1016\/j.tranon.2026.102958_bib0004","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.jtho.2016.09.001","article-title":"EGFR-Co-mutated advanced NSCLC and response to EGFR tyrosine kinase inhibitors","volume":"12","author":"Barnet","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"9","key":"10.1016\/j.tranon.2026.102958_bib0005","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41568-019-0179-8","article-title":"Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy","volume":"19","author":"Skoulidis","year":"2019","journal-title":"Nat. Rev. Cancer"},{"issue":"9","key":"10.1016\/j.tranon.2026.102958_bib0006","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.tranon.2026.102958_bib0007","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \"biological missile\" for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"19","key":"10.1016\/j.tranon.2026.102958_bib0008","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1200\/JCO.23.01909","article-title":"Datopotamab deruxtecan in advanced or metastatic HR+\/HER2- and triple-negative breast cancer: results from the phase I TROPION-PanTumor01 study","volume":"42","author":"Bardia","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"29","key":"10.1016\/j.tranon.2026.102958_bib0009","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1200\/JCO.23.02767","article-title":"Efficacy and safety of sacituzumab govitecan in patients with advanced solid tumors (TROPiCS-03): analysis in patients with advanced endometrial cancer","volume":"42","author":"Santin","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.tranon.2026.102958_bib0010","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1200\/JCO-24-01349","article-title":"Datopotamab deruxtecan in advanced or metastatic non-small cell lung cancer with actionable genomic alterations: results from the phase II TROPION-Lung05 study","volume":"43","author":"Sands","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.tranon.2026.102958_bib0011","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1200\/JCO.24.00733","article-title":"Sacituzumab govitecan versus Docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III EVOKE-01 study","volume":"42","author":"Paz-Ares","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.tranon.2026.102958_bib0012","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1200\/JCO-24-01544","article-title":"Datopotamab Deruxtecan versus Docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III TROPION-Lung01 study","volume":"43","author":"Ahn","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.tranon.2026.102958_bib0013","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41523-023-00573-8","article-title":"Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan","volume":"9","author":"Zhao","year":"2023","journal-title":"NPJ Breast Cancer"},{"issue":"5","key":"10.1016\/j.tranon.2026.102958_bib0014","doi-asserted-by":"crossref","first-page":"560","DOI":"10.18632\/oncotarget.27342","article-title":"Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas","volume":"11","author":"Lopez","year":"2020","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.tranon.2026.102958_bib0015","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-21-0206","article-title":"Datopotamab Deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells","volume":"20","author":"Okajima","year":"2021","journal-title":"Mol. Cancer Ther."},{"issue":"9","key":"10.1016\/j.tranon.2026.102958_bib0016","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.annonc.2021.06.002","article-title":"Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.tranon.2026.102958_bib0017","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/s41416-020-01202-y","article-title":"The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage response","volume":"124","author":"Coleman","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"21","key":"10.1016\/j.tranon.2026.102958_bib0018","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1200\/JCO.23.00013","article-title":"Antibody-drug conjugates in lung cancer: recent advances and implementing strategies","volume":"41","author":"Passaro","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.tranon.2026.102958_bib0019","doi-asserted-by":"crossref","first-page":"679","DOI":"10.21037\/tcr-24-1870","article-title":"Deciding where Trop-2 directed antibody drug conjugates work in non-small cell lung cancer: the not so straightforward road","volume":"14","author":"Hsu","year":"2025","journal-title":"Transl. Cancer Res."},{"issue":"10","key":"10.1016\/j.tranon.2026.102958_bib0020","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrc1977","article-title":"Topoisomerase I inhibitors: camptothecins and beyond","volume":"6","author":"Pommier","year":"2006","journal-title":"Nat. Rev. Cancer"}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326002949?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326002949?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:44:47Z","timestamp":1790739887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523326002949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":20,"alternative-id":["S1936523326002949"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102958","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro evaluation of sacituzumab govitecan in non-small cell lung cancer with actionable genomic alterations","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102958","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102958"}}